Aqueous extract of Evodia lepta Merr. attenuates influenza virus infection via inhibition of the HSP90/NF-κB axis.

ETHNOPHARMACOLOGICAL RELEVANCE

Evodia lepta Merr. (ELM), a traditional medicinal herb widely used in southern China and Southeast Asia, has been historically applied for the treatment of febrile illnesses and flu-like symptoms. Previous studies have reported its anti-inflammatory and antiviral properties, but its efficacy against influenza virus infection remains largely unexplored.

AIM OF THE STUDY

To evaluate the anti-influenza activity of the aqueous extract of ELM and elucidate its underlying mechanisms, particularly the role of HSP90/NF-κB signaling axis.

MATERIALS AND METHODS

The chemical constituents of ELM were characterized using UPLC-MS. A murine model of H1N1 influenza infection was established to assess the protective efficacy of ELM. Disease progression was evaluated through clinical symptoms, survival, histopathology, and inflammatory cytokine levels. Viral load and protein expression were assessed via RT-qPCR, Western blot, and immunohistochemistry. Network pharmacology was used to identify candidate targets, which were validated in vivo. The role of HSP90 was further confirmed using a selective inhibitor (AUY922). A combination study with oseltamivir evaluated potential synergistic effects.

RESULTS

Ten major bioactive compounds were identified in ELM. Oral administration of ELM significantly improved body weight recovery, reduced morbidity and mortality, and alleviated lung pathology in H1N1-infected mice. ELM markedly decreased viral replication and pro-inflammatory cytokine levels. Mechanistic investigations revealed that ELM suppressed the expression of HSP90, a host chaperone essential for influenza virus polymerase function. Combination therapy with oseltamivir demonstrated enhanced antiviral efficacy, indicating a synergistic effect.

CONCLUSION

ELM exerts significant therapeutic effects against influenza virus infection in vivo, likely through inhibition of HSP90/NF-κB signaling axis. These findings support the potential of ELM as a novel antiviral agent or adjunct therapy for the treatment of influenza.